Characterization of the In Vivo Consequences of Salicylate Co-Administration on the Efficacy of Topoisomerase II Poison-Based Chemotherapy in a Model of Human Breast Cancer

Simple item page
atmire.migration.oldid5346
dc.contributor.advisorKurz, Ebba
dc.contributor.authorCrovetto, Gina Marie Alexandra
dc.contributor.committeememberLees-Miller, Susan
dc.contributor.committeememberMorris, Donald
dc.date.accessioned2017-02-02T17:30:02Z
dc.date.available2017-02-02T17:30:02Z
dc.date.issued2017
dc.date.submitted2017en
dc.description.abstractHuman DNA topoisomerase IIα (TOP2A) is an essential enzyme that resolves the topological complexities of DNA, via transient DNA double-strand breaks (DSBs), during replication, transcription, and mitosis. Several gold-standard chemotherapeutics used for treating breast cancer are TOP2 poisons, which act by covalently trapping TOP2-DNA complexes leading to an accumulation of cytotoxic DNA DSBs. Salicylate, the primary metabolite of aspirin, catalytically inhibits DNA cleavage by TOP2A and is known to attenuate TOP2 poison cytotoxicity in MCF-7 breast cancer cells. Given, the widespread use of aspirin and other salicylate derivatives, determining their effects on chemotherapeutic efficacy could have far-reaching implications. To address this, a panel breast cancer cell lines was compiled to further characterize the effect of salicylate on TOP2 poison cytotoxicity. Following the in cyto work, a murine xenograft model of human breast cancer was used to evaluate the in vivo consequences of salicylate co-administration on TOP2 poison-based chemotherapy.en_US
dc.identifier.citationCrovetto, G. M. (2017). Characterization of the In Vivo Consequences of Salicylate Co-Administration on the Efficacy of Topoisomerase II Poison-Based Chemotherapy in a Model of Human Breast Cancer (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/25293en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/25293
dc.identifier.urihttp://hdl.handle.net/11023/3638
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectAnimal Physiology
dc.subjectBiology--Cell
dc.subjectBiology--Molecular
dc.subjectOncology
dc.subjectPharmacology
dc.subjectChemistry--Pharmaceutical
dc.subject.otherTopoisomerase IIa
dc.subject.otherSalicylate
dc.subject.otherAcetylsalicylic Acid
dc.subject.otherCancer Biology
dc.subject.otherXenograft
dc.subject.otherDoxorubicin
dc.subject.otherEtoposide
dc.subject.otherCytotoxicity
dc.subject.otherChemotherapy
dc.subject.otherTranslational Research
dc.subject.otherTOP2A
dc.titleCharacterization of the In Vivo Consequences of Salicylate Co-Administration on the Efficacy of Topoisomerase II Poison-Based Chemotherapy in a Model of Human Breast Cancer
dc.typemaster thesis
thesis.degree.disciplineMedical Science
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations